Marketing Application For Vernakalant Intravenous (IV) Filed In Europe For The Treatment Of Atrial Fibrillation

Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company's Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).